Athersys licenses regenerative medicine therapy to Healios for treatment of stroke in Japan

Client(s) Athersys, Inc.

Jones Day acted as intellectual property and tax counsel in the collaboration of Athersys, Inc. and Healios for the development and commercialization of novel stem cell therapy treatments, using Athersys' MultiStem cell. The license granted is initially for the treatment of ischemic stroke, but contains an option to be expanded. The license also includes right to use such cells for "organ bud" technology for liver transplant.